User profiles for Christopher P Conlon
 | Christopher ConlonProfessor of Infectious Diseases, Oxford University Verified email at ndm.ox.ac.uk Cited by 25253 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
…, H Clark, E Clark, T Cole, R Colin-Jones, CP Conlon… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
…, JS Cho, L Cifuentes, E Clark, S Collins, CP Conlon… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
…, RJ Cornall, CP Conlon, P Klenerman… - Nature …, 2020 - nature.com
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
Antibody status and incidence of SARS-CoV-2 infection in health care workers
…, DW Crook, AM O'Donnell, CP Conlon… - … England Journal of …, 2021 - Mass Medical Soc
Background The relationship between the presence of antibodies to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains …
syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains …
[PDF][PDF] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
…, L Stafford, S Johnson, DG Wootton, CP Conlon… - Cell, 2021 - cell.com
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
Rapid Detection of Mycobacterium tuberculosisInfection by Enumeration of Antigen-specific T Cells
…, RJ Wilkinson, M Latif, CP Conlon… - American journal of …, 2001 - atsjournals.org
There is no reliable means of detecting latent M. tuberculosis infection, and even in patients
with active tuberculosis, infection is often unconfirmed. We hypothesized that M. tuberculosis …
with active tuberculosis, infection is often unconfirmed. We hypothesized that M. tuberculosis …
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study
…, B Holthof, AM O'Donnell, D Ebner, CP Conlon… - elife, 2020 - elifesciences.org
We conducted voluntary Covid-19 testing programmes for symptomatic and asymptomatic
staff at a UK teaching hospital using naso-/oro-pharyngeal PCR testing and immunoassays for …
staff at a UK teaching hospital using naso-/oro-pharyngeal PCR testing and immunoassays for …
[PDF][PDF] A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete
description of specific immune biomarkers. We present here a comprehensive multi-omic …
description of specific immune biomarkers. We present here a comprehensive multi-omic …
[HTML][HTML] T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre …
Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern
, … Duncan Christopher JA 30 31 Payne Rebecca P … - Nature …, 2021 - nature.com
The extent to which immune responses to natural infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants …
syndrome coronavirus 2 (SARS-CoV-2) and immunization with vaccines protect against variants …
